Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level
Open Access
- 1 December 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (6) , 1214-1225
Abstract
Dihydrotestosterone and testosterone are thought to be major contributors of prostate cancer progression and resistance. We studied the modulation of 15 circulating steroids by castration and their association with dihydrotestosterone and testosterone levels. A total of 116 serum samples were collected from 99 prostate cancer patients and categorized as eugonadal, castration-sensitive prostate cancer, castration-resistant prostate cancer, or castration-resistant prostate cancer under abiraterone acetate. Serum levels of 15 steroids were measured using mass spectrometry and compared between groups using analysis of variance. Intrapatient association of steroid levels and the androgens testosterone and dihydrotestosterone were assessed using Pearson correlation and linear regression. Testosterone, dihydrotestosterone, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androsterone, androstenediol, estrone, estrone-sulfate, estradiol, and androsterone/3α-diol-3/3α-diol-17-glucuronide levels were significantly decreased in castration-sensitive prostate cancer (castrated) compared to eugonadal patients. Testosterone levels were strongly associated with multiple steroids under eugonadal conditions, whereas they were weakly affected by precursor steroids in castrated patients. By contrast, dihydrotestosterone levels under androgen deprivation therapy were associated with testosterone and the backdoor pathway metabolite androsterone. In castration-resistant prostate cancer patients, levels of androstenedione were significantly associated with testosterone level, while testosterone was the only steroid associated with dihydrotestosterone levels. Androgen deprivation therapy significantly reduces the levels of 13 circulating steroids. Upon androgen deprivation therapy initiation, the backdoor pathway metabolite androsterone are strongly associated with dihydrotestosterone levels. Under castration-resistant prostate cancer conditions, androstenedione was significantly associated with testosterone levels, suggesting the presence of tumor-related circulating androgens in these patients. These results provide further rationale to intensify treatments with androgen receptor axis signaling pathway inhibitors in patients with prostate cancer.Keywords
This publication has 30 references indexed in Scilit:
- Evidence of Limited Contributions for Intratumoral Steroidogenesis in Prostate CancerCancer Research, 2010
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate CancerCancer Research, 2008
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor GrowthCancer Research, 2008
- Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implicationsBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate CancerClinical Cancer Research, 2005
- Pretreatment Serum Testosterone Level as a Predictive Factor of Pathological Stage in Localized Prostate Cancer Patients Treated with Radical ProstatectomyEuropean Urology, 2005
- The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate CancerClinical Cancer Research, 2004
- Testicular Androgens in Prostate Cancer Patients Treated with a Luteinizing Hormone Releasing Hormone AgonistJournal of Urology, 1994
- Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118?630) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancerUrological Research, 1991